



ASX/MEDIA RELEASE

10th April 2017

Mr Neville Mitchell Appointed Non-Executive Director

Sydney, Australia; 10th April 2017 – Sirtex Medical Limited (ASX:SRX) is pleased to announce that Mr Neville Mitchell has been appointed as an Independent Non-Executive Director of the Company, effective from 10th April 2017.

Mr Richard Hill, Chairman of Sirtex Medical commented “Neville is one of the most experienced senior executives in the Australian medical device industry, with a demonstrated track record of success and achievement. He will make a valuable addition to the Board of Directors as Sirtex progressively reports its major clinical studies and grows the awareness and use of SIR-Spheres[®] Y-90 resin microspheres globally.”

Mr Mitchell has over 25 years of experience as the former Chief Financial Officer and Company Secretary of Cochlear Limited (ASX:COH), the world's leading medical device company for the development, manufacture and sale of cochlear implants with annual revenue in excess of \$1 billion. Mr Mitchell was a key member of Cochlear's executive team responsible for the setting and execution of the Company's growth strategy since its listing on the ASX in 1995 with a market capitalisation of \$125 million. The success of this growth strategy has resulted in Cochlear's market capitalisation increasing to over \$7 billion today.

During his time at Cochlear, Mr Mitchell was responsible for all financial aspects of the business, including ASX compliance and governance, banking, acquisitions and mergers, together with forecasting/budgetary management and responsibility for accounting data, legal and company secretarial and facilities. He is currently a Director of Osprey Limited (ASX:OSP), the South East Sydney Local Health District and a member of the Board of Taxation.

Mr Mitchell said “I am delighted to be joining the Board of Sirtex at such an important time in the Company's development. The emergence of minimally invasive medical devices such as SIR-Spheres microspheres for the targeted treatment of cancer represents an attractive long term growth opportunity globally, which I am pleased to be a part of.”

About SIR-Spheres[®] Y-90 Resin Microspheres

SIR-Spheres Y-90 resin microspheres are a medical device used in interventional oncology and delivered via Selective Internal Radiation Therapy (SIRT), also known as radioembolisation, directly to liver tumours. SIR-Spheres Y-90 resin microspheres are approved for supply in key markets, such as the United States, European Union and Australia.

Head Office
Level 33, 101 Miller Street
North Sydney, NSW 2060
Australia

Americas
300 Unicorn Park Drive
Woburn, MA 01801
United States

Europe, Middle East & Africa
Josef-Schumpeter-Allee 33
53227 Bonn
Germany

Asia Pacific
50 Science Park Road, #01-01
The Kendall Science Park II
Singapore 117406

About Sirtex Medical

Sirtex Medical Limited (ASX:SRX) is an Australian-based global healthcare business working to improve outcomes in people with cancer. Our current lead product is a targeted radiation therapy for liver cancer. Over 73,000 doses have been supplied to treat patients with liver cancer at 1,060 medical centres in over 40 countries. For more information please visit www.sirtex.com.

For further information, please contact:

Investor Enquiries:

Mr Richard Hill
Chairman
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8400

Investor/Media Enquiries:

Dr Tom Duthy
Global Investor Relations Manager
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8427
Email: tduthy@sirtex.com